Berwyn, PA, United States of America

Ponnal Nambi


Average Co-Inventor Count = 2.7

ph-index = 3

Forward Citations = 33(Granted Patents)


Company Filing History:


Years Active: 1996-2009

Loading Chart...
6 patents (USPTO):Explore Patents

Title: Ponnal Nambi: Innovator in Pharmaceutical Compositions

Introduction

Ponnal Nambi is a distinguished inventor based in Berwyn, PA (US). He has made significant contributions to the field of pharmaceuticals, holding a total of 6 patents. His work focuses on innovative compounds and their applications in treating various diseases.

Latest Patents

Among his latest patents, Nambi has developed compounds related to quinolines and pharmaceutical compositions. This invention provides compounds of formula I that are useful in the treatment or inhibition of LXR mediated diseases. Additionally, he has patented novel human LXRα variant polypeptides and nucleic acids encoding such polypeptides. This invention also highlights the therapeutic, diagnostic, and research utilities, as well as the production of such polynucleotides and polypeptides. It is important to note that this abstract is provided to comply with the rules requiring an abstract that will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure.

Career Highlights

Throughout his career, Ponnal Nambi has worked with prominent companies in the pharmaceutical industry, including SmithKline Beecham Corporation and Wyeth. His experience in these organizations has contributed to his expertise and innovative capabilities in the field.

Collaborations

Nambi has collaborated with notable coworkers such as Ashok D Patil and Yuan Zhu, further enhancing his contributions to pharmaceutical research and development.

Conclusion

Ponnal Nambi's work in the field of pharmaceuticals showcases his innovative spirit and dedication to advancing medical science. His patents reflect a commitment to developing effective treatments for LXR mediated diseases, making a significant impact in the industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…